Women's health in women's hands : a pilot study assessing the feasibility of providing women with medications to reduce postpartum hemorrhage and sepsis in rural Tanzania by Webber, Gail C. & Chirangi, Bwire
Full Terms & Conditions of access and use can be found at
https://www.tandfonline.com/action/journalInformation?journalCode=uhcw20
Health Care for Women International
ISSN: 0739-9332 (Print) 1096-4665 (Online) Journal homepage: https://www.tandfonline.com/loi/uhcw20
Women's Health in Women's Hands: A Pilot Study
Assessing the Feasibility of Providing Women With
Medications to Reduce Postpartum Hemorrhage
and Sepsis in Rural Tanzania
Gail C. Webber & Bwire Chirangi
To cite this article: Gail C. Webber & Bwire Chirangi (2014) Women's Health in Women's
Hands: A Pilot Study Assessing the Feasibility of Providing Women With Medications to Reduce
Postpartum Hemorrhage and Sepsis in Rural Tanzania, Health Care for Women International,
35:7-9, 758-770, DOI: 10.1080/07399332.2014.915843
To link to this article:  https://doi.org/10.1080/07399332.2014.915843
© 2014 The Author(s). Published with
license by Taylor & Francis© Gail C. Webber
and Bwire Chirangi
Published online: 01 Jul 2014.
Submit your article to this journal Article views: 2083
View related articles View Crossmark data
Citing articles: 2 View citing articles 
Health Care for Women International, 35:758–770, 2014
Published with license by Taylor & Francis
ISSN: 0739-9332 print / 1096-4665 online
DOI: 10.1080/07399332.2014.915843
Women’s Health in Women’s Hands: A Pilot
Study Assessing the Feasibility of Providing
Women With Medications to Reduce
Postpartum Hemorrhage and Sepsis
in Rural Tanzania
GAIL C. WEBBER
Department of Family Medicine, University of Ottawa, Ottawa, Ontario, Canada
BWIRE CHIRANGI
Shirati District Hospital, Shirati, Tanzania
In rural Africa, deaths from childbirth are common and access to
health care facilities with skilled providers is very limited. Leading
causes of death for women are bleeding and infection. In this pilot
study, we establish the feasibility of distributing oral medications
to women in rural Tanzania to self-administer after delivery to
reduce bleeding and infection. Of the 642 women provided with
medications, 90% of the women took them appropriately, while the
remaining 10% did not require them. We conclude that is it feasible
to distribute oral medications to rural women to self-administer
after delivery.
Context of Maternal Mortality in Africa
Death from childbirth is one of the largest challenges facing African women
today, particularly in rural communities. The United Nations’ fifth Millennium
Development Goal addressed this concern with the aim to improve maternal
health and reduce by two-thirds by 2015 the enormously high numbers of
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women dying while giving birth (United Nations, 2013). Although, several
African countries have made some progress toward this goal, there are still
many thousands of women dying as a result of childbirth annually. In 2010,
an estimated 164,800 women lost their lives while giving birth in Africa—56%
of the number of women dying globally of childbirth (African Union Commis-
sion, Economic Commission for Africa, African Development Bank Group,
& United Nations Development Program, 2013). In Tanzania, with a mater-
nal mortality ratio of 454 per 100,000 (National Bureau of Statistics Tanzania
& ICF Macro Tanzania, 2011), this reality equates to one woman dying in
childbirth almost hourly (Ministry of Finance and Economic Affairs, Republic
of Tanzania, 2009).
Two of the largest causes of maternal mortality are bleeding and infec-
tion, causing 25% and 15% of maternal deaths globally, respectively (Sullivan
& Hirst, 2011). In Africa, 34% of maternal deaths are attributed to hemorrhage
(Haeri & Dildy, 2012). Women who deliver outside of a health care institu-
tion are most at risk, as they do not have access to life-saving medications or
skilled attendants. More than 50% of women delivering in sub-Saharan Africa
lack a skilled birth attendant at their delivery, and there is evidence that this
concerning statistic is unlikely to change soon (Crowe, Utley, Costello, &
Pagel, 2012). In addition to increasing access to health care services for rural
women, strategies are urgently needed to provide women with alternative
methods to reduce their risks at the time of delivery that are not dependent
on the presence of skilled health care workers.
Postpartum Hemorrhage
Saving mothers’ lives from the risks of childbirth does not always involve
costly interventions. The recommendations for the period immediately after
delivery of the baby, referred to as the third stage of labor, are to provide
injectable uterotonic medications such as oxytocin or ergometrine to prevent
bleeding. Unfortunately, for women delivering in the villages or on the way
to a facility, this is not possible as these medications require refrigeration
and a skilled provider to administer them. Six hundred micrograms of oral
misoprostol has been shown to be an effective alternative to injectable utero-
tonics in low-resource settings (Gülmezoglu, Forna, Villar, & Hofmeyr, 2011;
Sheldon, Blum, Durocher, & Winikoff, 2012). The World Health Organiza-
tion (WHO) and the International Federation of Gynecology and Obstetrics
(FIGO) have both endorsed the use of misoprostol for the prevention of
postpartum hemorrhage (PPH) in settings where oxytocin in not available,
although only when administered by a skilled or lay health care provider
(FIGO Safe Motherhood and Newborn Committee, 2012; WHO, 2012a). The
United Nations Commission on Life-Saving Commodities for Women and
Children has listed misoprostol for the prevention and treatment of PPH as
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one of 13 key commodities to reduce deaths of women and children (Every
Women Every Child, 2012).
Community distribution of misoprostol for PPH prevention through var-
ious providers has been demonstrated to be effective in India (Derman et al.,
2006), Afghanistan (Sanghvi et al., 2010), Nepal (Rajbhandari et al., 2010),
Bangladesh (Nasreen, Nahar, Al Mamun, Afsana, & Byass, 2011), and Pak-
istan (Mir Wajid, & Gull, 2012), as well as several other countries in Africa
and Asia (Smith, Gubin, Holston, Fullerton, & Prata, 2013). In Tanzania, there
have been two studies of misoprostol for PPH prevention. In the first (Prata,
Mbaruki, Grossman, Holston, & Hsieh, 2009), misoprostol was successfully
distributed through traditional birth attendants (TBAs). Unfortunately, this
is no longer feasible as the Tanzanian government has officially restricted
the work of TBAs, and while women still attend these caregivers, it is un-
likely that TBAs would be permitted to engage in misoprostol distribution.
In the second study, the intervention entailed dispensary nurses delivering
misoprostol at the antenatal visits after 32 weeks gestation (Ifakara Health In-
stitute, Venture Strategies Innovations, Bixby Center for Population, Health
and Sustainability, Population Services International [PSI]/Tanzania, 2011);
however, the researchers found that many women did not receive the med-
ications because they did not attend antenatal care during the latter weeks
of their pregnancy. The WHO has recognized that task shifting needs to
occur in maternal and child health in order to optimize care, but, they have
stopped short of promoting misoprostol distribution to pregnant women for
self-administration to prevent PPH (WHO, 2012b).
Puerperal Sepsis
In addition to PPH, puerperal sepsis, or life-threatening infection associated
with childbirth, is another major cause of death for mothers. Puerperal sep-
sis has been estimated to contribute to 75,000 deaths per year, mostly in
developing countries (Hussein & Fortney, 2004). It has been proposed that
the provision of antibiotics to prevent life-threatening sepsis and oral miso-
prostol to prevent postpartum bleeding could augment facility strengthening
in Africa to reduce deaths from childbirth by one-third (Pagel et al., 2009).
There is evidence that prophylactic antibiotic use prevents sepsis in elec-
tive and nonelective caesarian sections and in women at high risk of sepsis
(van Dillen, Zwart, Schutte & van Roosmalen, 2010). In a study of prophy-
lactic antibiotics at delivery in HIV-positive women, researchers have also
documented a reduction in postpartum infections (Sebitloane, Moodley, &
Esterhuizen, 2008), although a study of HIV infected and noninfected women
was unable to demonstrate a positive effect of prophylactic antibiotics given
during the antenatal and intrapartum periods to women in urban health care
facilities in Malawi, Tanzania, and Zambia (Aboud et al., 2009).
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Purpose and Objectives
In order to address the problem of maternal mortality for rural women living
in Rorya District, Tanzania, we conducted a 6-month study in 2012. The
purpose of this research was to assess the feasibility of misoprostol and
erythromycin distribution to rural Tanzanian women to prevent PPH and
puerperal sepsis. Our objectives were to demonstrate that the community
provision of these medications was both acceptable to the community and




This research used a mixed method design composed of both quantitative
and qualitative methods. After receiving the study medications, the women
were surveyed by the research assistants about their demographic informa-
tion and the facts of their delivery experience (quantitative results). The
results of the survey are the focus of this article. In addition, interviews were
conducted with women, traditional birth attendants, and dispensary nurses;
these results are reported elsewhere (Webber & Chirangi, n.d.).
Research Setting
Rorya District is bordered by Lake Victoria to the west, Serengeti National
Park to the east, and the Kenyan border to the north. Mara Region has one
of the highest nonfacility birth rates in Tanzania, with more than 60% of
women delivering in their villages where no skilled attendants are available
(Ministry of Finance and Economic Affairs, Republic of Tanzania, 2009). We
chose to conduct the study in the villages serviced by 12 rural dispensaries
in Rorya that were located farthest from the district hospital.
Ethics and Data Collection
Ethical approval for the study was obtained from the Ottawa Hospital Re-
search Ethics Board in Canada and the National Institute of Medical Research
in Tanzania, which is responsible for ethical approval of all medical research
in Tanzania.
In this study, research assistants and dispensary nurses distributed miso-
prostol and erythromycin to rural women for self-administration after delivery
(i.e., the women could take the medication themselves or designate a family
member or TBA to administer it to them). We used a misoprostol dose of
600 micrograms because this is the recommended dose for prevention of
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PPH (WHO, 2011). We included 500 mg of erythromycin, an antibiotic that
is used to treat Group A streptococcus, historically a common cause of puer-
peral sepsis (Hussein & Fortney, 2004). It is important to note that in order
to maximize distribution, we provided these medications to women during
their pregnancy for self-administration after delivery and we attempted to in-
clude all willing women in the catchment area, not just those who attended
antenatal clinics for prenatal care, unlike some previous studies (Smith et al.,
2013).
From February to July 2012, the research assistants visited the study vil-
lages and with the assistance of local health workers, they met with women
who were currently pregnant and due to deliver before August. In addition to
distributing the medications directly from the research assistants, the dispen-
sary nurses were provided with the study medications and were instructed
how to enroll women in the study. The research assistants and dispensary
nurses explained the study to the women in the local language of Swahili
or Luo, and they provided an information letter in Swahili to the women.
The women were asked to sign a consent form indicating their agreement to
participate in the study. The consent form was read to women who lacked
the literacy skills to read it themselves. Women who consented to be part
of the study were provided with a small bag containing three tablets of
misoprostol (200 micrograms each) and two tablets of erythromycin (250 mg
each). The women were instructed to store the medication in a safe location,
to take it with them wherever they chose to deliver, and to swallow the
medications immediately after the birth of the infant and not before. The
women were also warned about the possible side effects of the medications,
particularly shivering and an upset stomach. We sought ethics permission
from the Canadian ethics committee to include only women 18 years and
older; hence younger women are not represented in this report.
After the women delivered, the research assistants returned to survey
them about their birth experience. The research assistants collected demo-
graphic information on the women (including age, parity, and distance living
from the hospital and dispensary), in addition to details about the delivery
(location, attendance at delivery, whether study medications were taken,
whether the woman would consider taking the study medications in future
deliveries, side effects, and the health of the baby).
Analysis and Validity
All data were entered into an Excel spreadsheet by the principal investigator
or a research assistant, and 20% of the data entries were double-entered for
accuracy. All errors were corrected. The data were then analyzed using SPSS
for descriptive statistics.
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RESULTS
A total of 642 women were surveyed after they used the study medications.
The results of the survey are provided in Table 1.
Demographic Information
The mothers’ ages ranged from 18 to 47, with a median age of 26. The
women’s parity also had a wide spread, from 1 to 14 with a median parity
of fou children. The median distance from the hospital for the women was
34 km, although the farthest was 90 km. The median distance from the
dispensary was 4 km, while the range extended from 0.25 km to 57 km.
Experience of Delivery
Most of the women surveyed delivered in their own home (47.9%) or the
TBA’s home (21.1%). A further 3.4% delivered en route to a health facility.
Thus 72.4% of this cohort of women delivered outside of a health care
facility. The remainder of the women delivered in a variety of health care
TABLE 1 Survey Results (n = 642)
Survey item Results
Age of mothers (years; n = 642) Range 18–47 (median 26)
Parity of mothers (n = 642) Range 1–14 (median 4)
Distance from hospital (km; n = 642) Range 2–90 (median 34)
Distance from dispensary (km; n = 640) Range 0.25–57 (median 4)
Place of delivery (n = 641) Home: 307 (47.9%)
TBA’s home: 135 (21.1%)
Dispensary: 83 (12.9%)
Hospital: 79 (12.3%)
On the way: 22 (3.4%)
Health center: 12 (1.9%)
Pharmacy: 3 (0.5%)
Attendance at delivery (n = 642) TBA: 244 (38.0%)
Family/neighbors only: 195 (30.4%)
Dispensary nurses: 97 (15.1%)
Hospital staff: 78 (12.1%)
Alone: 22 (3.4%)
Others: 6 (0.9%)




∗All received injection at institution.
Number who would take study
medications again in future
pregnancies (n = 642)
Yes: 640 (99.7%)
No: 2 (0.3%)∗
∗One wanted tubal ligation, one had not used
meds.
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facilities: dispensary (12.9%), hospital (12.3%), health center (1.9%), and local
pharmacy (0.5%).
More than two-thirds of the women were not attended by a skilled health
care provider for their delivery. About one-third was either alone (3.4%), or
only with family or neighbors (30.4%), or with others (0.9%). More than one-
third (38%) were attended by a TBA. The remaining women had the skilled
attendance of a dispensary nurse (15.1%) or hospital staff (12.1%).
When asked about whether they took the study medications, 90% of
the women stated they did. The remaining 10% who did not take the med-
ications all received an injectable medication at a health care institution,
and thus they did not require the study medications. Of note, some of the
women who delivered in an institution where injectable medication was
available still insisted on using the study medication, despite the instructions
of the health care staff to accept the injectable medication. All the women
except for two, including those who had not used the medication, stated
they would take them in a future pregnancy. Of the two who declined, one
had not used the medications, and the second did not intend to have more
children.
The women were asked if they sought medical attention for bleeding
(n = 641). The vast majority (99.4%) stated they did not. Of the four women
who admitted to requiring further attention for bleeding, two women had
bleeding after using the misoprostol. One of these women got assistance from
a health care provider and received injectable medication, while the other
received local medications. The other two women who bled had received
injectable medications first, and subsequently they decided to take the study
medications.
When asked if they sought medical attention for infection, 636 of the
642 women surveyed (99.1%) stated that they did not. The six women who
did seek medical attention for infection just reported on side effects. One
of the six had not received misoprostol. Of the five women who had used
the misoprostol, three reported abdominal pain, while one each reported
palpitations and lack of energy. Two women stated that they subsequently
used traditional medicine.
The women were also asked if the baby was born healthy (n = 641).
For 631 women (98.4%), they agreed that the baby was healthy. For the
remaining 10 women (1.6%), the responses follow: death of baby for seven
(from prematurity, cord around neck, convulsions), spontaneous abortion
(one), prematurity at 7 months (one), and no reason given (one).
DISCUSSION
About half of the women surveyed lived more than 30 km from the hos-
pital and more than 4 km from the dispensary, and most had no access to
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transportation. A total of 72.4% of this cohort delivered outside of a health
care facility. This percentage is higher than the average for the region (Min-
istry of Finance and Economic Affairs, Republic of Tanzania, 2009). Such a
statistic is not surprising, however, as we chose to conduct this project in
the most rural dispensaries in the district. There are many barriers to women
in this region reaching a facility for delivery, including geographic distances,
lack of affordable transportation, and insufficient time to undertake the trip
before delivery.
An earlier study also documented multiple barriers facing Tanzanian
women seeking a facility delivery (Women’s Dignity and CARE International
in Tanzania, 2008). In this study, women noted that in addition to distance
and cost of delivery at a health care facility, the negative attitudes of health
care providers and the lack of qualified staff and supplies were other bar-
riers to seeking a health care facility for childbirth. Despite the existence
of multiple barriers, Mbaruku and colleagues have demonstrated that many
Tanzanian women would prefer a facility birth over birthing with a TBA if
they had the choice because they are aware of the need for a skilled birth
attendant to ensure a safe delivery (Mbaruku, Msambichaka, Galea, Rockers,
& Kruk, 2009).
Only about a quarter of women in our cohort were attended by a trained
health care provider, and a third of the women delivered without even the
presence of a TBA. Interventions to help these women will be most effective
if they can be easily administered by the women themselves or by those who
are with her at the time of delivery. While the challenges for women to attend
health care facilities for delivery are significant, the women who participated
in our study were very positive about the availability of oral medications for
them to take. All the women who took the study medications would use them
again. Indeed, almost all of the women who did not take them would also
use them in another pregnancy, as the word had spread about how effective
the medications were. In future studies, more education about available
drugs and their effectiveness is needed as some of the participating women
chose to use misoprostol even when the superior medication oxytocin was
available at a health care facility. Community distribution of misoprostol
will help ensure that women have access to a uterotonic drug at the time
of delivery for prevention of PPH, as the lower-level health care facilities
(e.g., dispensaries) often do not have oxytocin in stock (Plotkin, Tibaijuka,
Makene, Currie, & Lacoste, 2010).
There is not enough evidence to warrant including an oral antibiotic for
sepsis prevention currently, and this will be abandoned in future research.
Instead, in our scale-up project we intend to provide rural women with
600 micrograms of misoprostol in combination with a birth kit. How to
effectively deliver these kits containing misoprostol to the most women has
yet to be determined (Smith et al., 2013) and will be a focus of future
research.
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Limitations
There were several limitations to the research. It was not feasible to random-
ize the population; therefore, a convenience sample of women was used.
Unfortunately, we were unable to include the TBAs in the distribution of the
misoprostol as current government policy has prohibited them from prac-
ticing (although many still service the rural population). We did not record
the number of women who declined to participate and the reasons for this;
however, the participating dispensary nurses could only recall one woman
who actively declined taking the study medications. Future research should
capture this data, including which family members are making the decision
for women to access care. We relied on self-report of the women about
using the medication, which could elicit some bias. In addition, we did not
confirm the timing of when the medication was taken; this oversight will be
addressed in the scale-up study. Finally, in the future we will seek ethics
approval to include younger women in the study (obtaining parental con-
sent for their participation), as it is not uncommon for women aged 14 to 17
to become pregnant in this region, and excluding them from access to this
important intervention because of age would be unethical.
Conclusions
Investment in maternal health is a human right, and results in improved
health for the whole family as mothers are the main caregivers for children.
It also makes economic sense, for every dollar spent on maternal health has
the potential to multiply twentyfold in economic benefits (The Partnership
for Maternal, Newborn and Child Health, 2013). Like thousands of women
living in rural Africa, many women in rural Tanzania lack the resources and
time to access health care providers at the time of their deliveries. Until there
is sufficient resources to construct and staff health care facilities in the most
rural areas of the country, there is a role for provision of oral medications for
home deliveries. Women are both willing and able to safely take oral medica-
tions provided to them in pregnancy at the time of their deliveries, even when
delivering at home with a TBA, family member, or alone. Through this study
we conclude that it is feasible to distribute misoprostol to women for self-
administration for PPH prevention, and in fact this is confirmed by a recent
review of the literature (Smith et al., 2013). Qualitative data from interviews
with participating women, TBAs, and dispensary nurses demonstrate that
this program is very acceptable to women, their health care providers, and
their communities (Webber & Chirangi, n.d.). As noted earlier, the benefits
of misoprostol in preventing PPH are well established (Derman et al., 2006;
Guülmezoglu et al., 2011; Sheldon, Blum, Durocher, & Winikoff, 2012) and
it is now recommended that misoprostol be provided at all deliveries where
access to injectable uterotonic medications is limited (FIGO, 2012; WHO,
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2012a). While the WHO has not yet endorsed the distribution of misoprostol
for self-administration for PPH prevention (WHO, 2012a, 2012b), we would
argue that there is an imperative to undertake larger studies demonstrat-
ing the safety and effectiveness of this. Hundreds of thousands of women
could be saved by access to this inexpensive medication: the time for further
research is now.
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